[Form 4] RECURSION PHARMACEUTICALS, INC. Insider Trading Activity
Recursion Pharmaceuticals insider transaction: The company's Chief Financial Officer reported a non-derivative transaction in the company's Class A common stock. The filing shows 7,057 shares were withheld as part of net settlement of restricted stock units to satisfy tax withholding at an average price of $4.83 per share, leaving the reporting person with 804,169 shares beneficially owned following the transaction. The filing identifies the transaction as an issuer withholding related to equity compensation rather than an open-market sale.
Transazione di insider di Recursion Pharmaceuticals: il Chief Financial Officer della società ha riportato una transazione non derivativa nelle Azioni comuni di Classe A della società. La pratica mostra che sono state ritenute 7.057 azioni come parte della liquidazione netta di unità azionarie vincolate per soddisfare le ritenute fiscali, a un prezzo medio di $4,83 per azione, lasciando al soggetto segnalante 804.169 azioni detenute in modo beneficiario a seguito della transazione. La pratica identifica la transazione come una ritenuta dell'emittente collegata alla compensazione azionaria piuttosto che una vendita sul mercato aperto.
Transacción interna de Recursion Pharmaceuticals: El Director de Finanzas de la empresa reportó una transacción no derivativa en las acciones comunes de Clase A de la empresa. El registro muestra que se retuvieron 7.057 acciones como parte de la liquidación neta de unidades de acciones restringidas para satisfacer las retenciones fiscales, a un precio medio de $4,83 por acción, dejando al informante con 804.169 acciones beneficiosas tras la transacción. El registro identifica la transacción como una retención por parte del emisor relacionada con la compensación de acciones, y no como una venta en el mercado abierto.
Recursion Pharmaceuticals 내부자 거래: 회사의 최고재무책임자(CFO)가 클래스 A 보통주에 대한 비파생 거래를 보고했습니다. 공시에는 7,057주가 원천징수로 보류되어 주식 보상에 따른 세금 원천징수를 충족시키기 위한 평균 주가 $4.83로, 거래 후 보고자의 실제 보유 주식 수가 804,169주로 귀속 주주로 남게 되었습니다. 공시에서 이 거래는 공개시장에서의 매도가 아닌, 주식 보상과 관련된 발행자 원천징수로 식별됩니다.
Transaktion d’initié chez Recursion Pharmaceuticals : Le directeur financier de la société a déclaré une transaction non dérivée sur les actions ordinaires de Classe A de l’entreprise. Le dossier indique que 7 057 actions ont été retenues dans le cadre du règlement net d’unités d’actions restreintes pour satisfaire les retenues d’impôt, à un prix moyen de 4,83 $ par action, laissant à la personne qui déclare 804 169 actions détenues bénéficiaires après la transaction. Le dossier identifie la transaction comme une retenue par l’émetteur liée à la rémunération en actions plutôt que comme une vente sur le marché libre.
Insidertransaktion bei Recursion Pharmaceuticals: Der Finanzvorstand des Unternehmens meldete eine nicht derivatives Transaktion in den Class-A-Stammaktien des Unternehmens. Die Einreichung zeigt, dass 7.057 Aktien einbehalten wurden im Rahmen der Nettobereinigung von Restricted Stock Units, um die Steuerabzüge zu erfüllen, zu einem durchschnittlichen Preis von 4,83 USD pro Aktie, sodass der meldepflichtige Anteil nach der Transaktion über 804.169 Aktien im Beneficial Ownership verfügte. Die Einreichung kennzeichnet die Transaktion als eine vom Emittenten einbehaltene Transaktion im Zusammenhang mit aktienbasierter Vergütung statt als Verkauf am offenen Markt.
معاملة داخلية من Recursion Pharmaceuticals: أفاد مدير الشؤون المالية في الشركة عن معاملة غير مشتقة في الأسهم العادية من الفئة أ للشركة. يظهر التسجيل أن تم حجز 7,057 سهماً كجزء من تسوية صافية لوحدات الأسهم المقيدة لتلبية حجز الضرائب عند سعر متوسط قدره $4.83 للسهم، مما ترك للمبلغ المبلغ عنه 804,169 سهماً مملوكة للمستفيد بعد الصفقة. يحدد التسجيل أن المعاملة هي حجز من الجهة المصدرة مرتبط بتعويض الأسهم بدلاً من بيع في السوق المفتوح.
Recursion Pharmaceuticals 内幕交易： 公司的首席财务官报告了一笔非派生交易，涉及公司的A类普通股。备案显示在净结算的受限股票单位中有7,057股被扣留以满足税收代扣，平均价格为每股4.83美元，交易后申报人持有的可获受益的股份为804,169股。备案将该交易标识为与股票薪酬相关的发行人扣留，而不是公开市场出售。
- Clear disclosure that the transaction was an issuer withholding related to RSU net settlement
- Substantial remaining ownership of 804,169 shares after the withholding, indicating continued alignment with shareholders
- 7,057 shares were disposed (withheld) to satisfy tax obligations, reducing the reporting person's holdings
- Transaction price of $4.83 per share indicates the withholding occurred at that price level
Insights
TL;DR: Routine issuer tax-withholding reduced the CFO's share count by a small amount; large remaining ownership suggests continued alignment with shareholders.
The transaction is categorized as an issuer withholding to cover tax obligations from restricted stock unit net settlement, not an open-market disposition. With 804,169 shares reported after the withholding, the reporting person retains a substantial beneficial position. The withheld quantity, 7,057 shares, is immaterial relative to the post-transaction holdings and appears administrative.
TL;DR: Administrative equity withholding for taxes is standard; disclosure is compliant and provides transparency on insider holdings.
The form discloses the nature of the withholding and the resulting beneficial ownership, meeting Section 16 transparency requirements. There is no indication of a change in overall ownership control or of a voluntary sale by the officer. Documentation of the withholding mechanism is helpful for governance record-keeping.
Transazione di insider di Recursion Pharmaceuticals: il Chief Financial Officer della società ha riportato una transazione non derivativa nelle Azioni comuni di Classe A della società. La pratica mostra che sono state ritenute 7.057 azioni come parte della liquidazione netta di unità azionarie vincolate per soddisfare le ritenute fiscali, a un prezzo medio di $4,83 per azione, lasciando al soggetto segnalante 804.169 azioni detenute in modo beneficiario a seguito della transazione. La pratica identifica la transazione come una ritenuta dell'emittente collegata alla compensazione azionaria piuttosto che una vendita sul mercato aperto.
Transacción interna de Recursion Pharmaceuticals: El Director de Finanzas de la empresa reportó una transacción no derivativa en las acciones comunes de Clase A de la empresa. El registro muestra que se retuvieron 7.057 acciones como parte de la liquidación neta de unidades de acciones restringidas para satisfacer las retenciones fiscales, a un precio medio de $4,83 por acción, dejando al informante con 804.169 acciones beneficiosas tras la transacción. El registro identifica la transacción como una retención por parte del emisor relacionada con la compensación de acciones, y no como una venta en el mercado abierto.
Recursion Pharmaceuticals 내부자 거래: 회사의 최고재무책임자(CFO)가 클래스 A 보통주에 대한 비파생 거래를 보고했습니다. 공시에는 7,057주가 원천징수로 보류되어 주식 보상에 따른 세금 원천징수를 충족시키기 위한 평균 주가 $4.83로, 거래 후 보고자의 실제 보유 주식 수가 804,169주로 귀속 주주로 남게 되었습니다. 공시에서 이 거래는 공개시장에서의 매도가 아닌, 주식 보상과 관련된 발행자 원천징수로 식별됩니다.
Transaktion d’initié chez Recursion Pharmaceuticals : Le directeur financier de la société a déclaré une transaction non dérivée sur les actions ordinaires de Classe A de l’entreprise. Le dossier indique que 7 057 actions ont été retenues dans le cadre du règlement net d’unités d’actions restreintes pour satisfaire les retenues d’impôt, à un prix moyen de 4,83 $ par action, laissant à la personne qui déclare 804 169 actions détenues bénéficiaires après la transaction. Le dossier identifie la transaction comme une retenue par l’émetteur liée à la rémunération en actions plutôt que comme une vente sur le marché libre.
Insidertransaktion bei Recursion Pharmaceuticals: Der Finanzvorstand des Unternehmens meldete eine nicht derivatives Transaktion in den Class-A-Stammaktien des Unternehmens. Die Einreichung zeigt, dass 7.057 Aktien einbehalten wurden im Rahmen der Nettobereinigung von Restricted Stock Units, um die Steuerabzüge zu erfüllen, zu einem durchschnittlichen Preis von 4,83 USD pro Aktie, sodass der meldepflichtige Anteil nach der Transaktion über 804.169 Aktien im Beneficial Ownership verfügte. Die Einreichung kennzeichnet die Transaktion als eine vom Emittenten einbehaltene Transaktion im Zusammenhang mit aktienbasierter Vergütung statt als Verkauf am offenen Markt.
FAQ
What transaction did the Recursion Pharmaceuticals (RXRX) insider report on Form 4?
How many shares does the reporting person beneficially own after the transaction?
Was the Form 4 transaction an open-market sale or an issuer withholding?
What price per share is shown for the withheld shares?
Which reporting person is identified on the Form 4?
Does the Form 4 show any derivative transactions or option activity?
